Valorization Team (together with DCVA)

Margien Boels is an Impact Officer at the Dutch Cardiovascular Alliance (DCVA), where she’s responsible for the commercialization & valorization of DCVA consortia into solutions for patients and scalable biomed start-ups. She obtained a master’s degree in Nutrition and Health from Wageningen University and continued her academic career pursuing a Ph.D. degree in Medicine from Leiden University Medical Center in 2016 with the project “The glomerular endothelial glycocalyx in diabetic nephropathy, as part of a consortium of the Dutch Kidney Foundation. Later one, she worked as a stakeholder manager and as a Medical affairs Manager for Nutricia Nederland Medical.

• LinkedIn - Margien Boels

Luc Schoppink strives to fast-track innovation from lab to patient through translation of promising cardiology research into scalable ventures, with the aim to accelerate development and commercialization. Prior to his role of Impact Officer at DCVA, Luc worked in the role of Senior Consultant for Catalyze-Group, where he helped leading researchers and companies in Biotech, Medtech and Healthtech secure financing for ambitious R&D projects. Luc has a background in Biomedical- and Neurosciences, as well as a degree in Life Science based Management and Entrepreneurship. Today, Luc is dedicated to help promising research and innovation to reach its full potential.

• LinkedIn - Luc Schoppink

With a broad academic background in biomedical sciences, engineering, and business, Dominique works to bridge the gap between academia and industry. Dominique thrives on innovation and connecting with brilliant minds pushing the boundaries of human knowledge.
With an investor-like mindset, Dominique analyses research projects and helps develop a translational strategy for early-stage innovations to attract investments and progress toward the clinic.
Optional: In her free time, you will find Dominique performing with her band, or planning her next trip.
Why Dominique is passionate about our mission: Too often, great science does not reach the patient. To truly create an impact, academia and industry need to come together. At RegMed XB, we are building an ecosystem to facilitate just that.

• LinkedIn - Dominique de Jong

Bernard Mulder, MD, MBA has more than two decades of experience in the life sciences industry. He worked for Organon for 12 years, of which he spent 10 years abroad in Asia, Europe and the USA. He held several medical, marketing, sales and managerial positions in the different countries. After returning to the Netherlands, he worked as Global VP Marketing, Sales and Business Development for Avantium Pharma.

In 2011, Bernard co-founded Eagle Rock Life Sciences to support life sciences enterprises from early start-ups to mature companies (hands-on) and also invested in start-ups. Most recently, he worked for Boehringer Ingelheim for the medical department. Bernard earned his medical degree at Leiden University and his MBA from New York Institute of Technology.

• LinkedIn - Bernard Mulder

Rob de Ree is Chair of valorization at the Dutch Cardiovascular Alliance (DCVA), co-manager along RegMed XB of FIRST, a joint early phase investment fund. Rob started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden. Rob joined Medtronic in 1996 where he worked in various sales and marketing roles, and then he moved to Crucell where he led the licensing business after which he joined BMEYE, a startup in hemodynamic monitoring where he serves as CEO until it was sold to Edwards Lifesciences.

Rob was subsequently CEO of Dezima Pharma, which was sold to Amgen in October 2015. Currently, Rob is operating partner at Biogeneration Ventures since 2016, serving on the board and in interim management positions in the fund’s portfolio companies. In addition, he is CEO of NorthSea Therapeutics and serves on the board of Mellon Medical.

• BGV - Rob de Ree

Jaap is Investment Manager, leading BGV’s Fonds InvesteringsRijpe Starters (FIRST) fund. He joins BGV from Utrecht Health Seed Fund where he was Fund Manager with oversight for a series of successful investments in health and life sciences companies such as TargED Biopharmaceuticals, NTrans Technologies and Moveshelf. Prior to this, Jaap was an Investment Manager and Senior Business Developer at Utrecht Holdings where he led a number of investments, including the investment in Quantib, which was successfully sold to RadNet, Inc. He directed over 15 intellectual property tech license deals including the MR-STAT technology to Philips Healthcare. Prior to this, Jaap held several roles at Philips Healthcare’s Image Guided Therapy business and corporate incubator. Jaap holds a master’s degree in Aerospace Engineering from Delft University of Technology.

• LinkedIn - Jaap de Bruin